Prudential Financial Inc Tcr2 Therapeutics Inc. Transaction History

Prudential Financial Inc

  • $70.5 Billion
  • Q1 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022
SELL
$2.11 - $2.94 $607,880 - $846,999
-288,095 Closed
0 $0
Q1 2022

May 13, 2022
BUY
$2.4 - $4.71 $595,680 - $1.17 Million
248,200 Added 622.13%
288,095 $795,000
Q4 2021

Feb 14, 2022
BUY
$4.58 - $8.34 $182,719 - $332,724
39,895 New
39,895 $186,000

About TCR2 THERAPEUTICS INC.

TCRR Quotes by TradingView
  • Ticker TCRR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,606,400
  • Description
  • TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...
More about TCRR
Track This Portfolio

Track Prudential Financial Inc Portfolio

Follow Prudential Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prudential Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Prudential Financial Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email